Design, synthesis and structure–activity relationships of novel biarylamine-based Met kinase inhibitors

Biarylamine-based inhibitors of Met kinase have been identified. Lead compounds demonstrate nanomolar potency in Met kinase biochemical assays and significant activity in the Met-driven GTL-16 human gastric carcinoma cell line. X-ray crystallography revealed that these compounds adopt a bioactive conformation, in the kinase domain, consistent with that previously seen with 2-pyridone-based Met kinase inhibitors. Compound 9b demonstrated potent in vivo antitumor activity in the GTL-16 human tumor xenograft model.

Graphical abstractBiarylamine-based inhibitors of Met kinase have been identified. Compound 9b demonstrated potent in vivo antitumor activity in the GTL-16 human tumor xenograft model.Figure optionsDownload full-size imageDownload as PowerPoint slide